A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy

摘要: Purpose Routine assessment was made of tumor metabolic activity as measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in Stage I non–small-cell lung cancer (NSCLC). This report describes PET correlates prospectively collected after stereotactic body radiotherapy (SBRT) for patients with medically inoperable NSCLC. Methods and Materials 14 consecutive NSCLC were enrolled. All received SBRT to 60–66 Gy three fractions. Patients underwent serial planned FDG-PET/computed fusion imaging before at 2, 26, 52 weeks SBRT. Results With median follow-up 30.2 months, no experienced local failure. One patient developed regional failure, 1 distant a second primary. The maximum standardized uptake value (SUV max ) 8.70. SUV values 6.04, 2.80, 3.58, respectively. low pre-SBRT more likely experience initial 2-week rises SUV, whereas high commonly had declines 2 treatment ( p = 0.036). Six 13 primary >3.5 12 months but remained without evidence disease failure on further follow-up. Conclusions A substantial proportion may have moderately elevated FDG-PET Thus, slightly should not be considered surrogate Our data do support routine receiving